Schering Aktiengesellschaft

Jenapharm Gmbh & Co. Kg

Margit Richter

Walter Elger

Birgitt Schneider

Olaf Peters

Sigfrid Schwarz

Gudrun Reddersen

Rolf Bohlmann

Dirk Kosemund

Alexander Hillisch

Hans-Peter Muhn

Ina Thieme

Thomas Michel

Ina Scherlitz-Hofmann

Gerd M&uuml;ller

Nico Braeuer

This invention relates to 8&#x3b2;-vinyl-11&#x3b2;-(&#x3c9;-substituted)alkyl-estra-1,3,5(10)-trienes of general formula I with ER&#x3b2;-antagonistic activity, process for their production, their intermediate products, pharmaceutical preparations that contain the compounds according to the invention, as well as their use for the production of pharmaceutical agents. The new compounds can be used for contraception in men and women without influencing other estrogen-sensitive organs such as the uterus or the liver. They are also suitable for treating benign or malignant proliferative diseases of the ovary, such as ovarian cancer and granulosa cell tumors.

8&#x3b2;-vinyl-11&#x3b2;-(&#x3c9;-substituted)alkyl-estra-1,3,5(10)-trienes

C13-substituted estra-1,3,5,(10)-trien-3-yl sulfamates, methods of preparing same, and pharmaceutical compositions containing these compounds

The invention relates to new sulfamate derivatives of 1,3,5(10)-estratriene derivatives of the general formula I ##STR1## wherein the 3-sulfamate moiety is acylated, sulfonated or amidosulfonated. Furthermore, methods for the production of the compound and pharmaceutical preparations containing this compound are described. The compounds according to the invention have an estrogenic effect.

Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for

Growing community of inventors

Jena, Germany

Margit Richter